Bone Marrow Transplantation

Article	Citations
When is a chimaera not a chimaera?	100
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Data Management Group – Poster Session (P725-P741)	83
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Van Bekkum Awards	80
Haploidentical-cord blood stem cell transplantation versus haploidentical stem cell transplantation for non-CR acute leukemia patients: a multicenter study	77
OBITUARY- Riccardo Saccardi (20th April 1956–19th February 2024)	75
Tandem hematopoietic stem cell transplant considerations in families with multiple siblings affected by DOCK8 deficiency	63
Prognostic impact of histopathologic features including histological grading and immunohistochemistry-positive cell counts in cytomegalovirus-gastrointestinal disease after allogeneic hematopoietic ce	60
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P919-P930)	50
DNA methylation in circulating leukocytes is a novel biomarker in multiple myeloma	47
Length of SARS-CoV-2 shedding in HCT recipients: an Infectious Disease Working Party of EBMT study	44
Real world experience using belumosudil for treatment of chronic graft versus host disease in children and young adults	40
Infection prevention practices among EBMT hematopoietic cell transplant centers: the EBMT Infectious Disease Working Party survey	39
T cell redirection as a new standard of care for relapsed multiple myeloma: impact on inpatient capacity, financial burden and infrastructural requirements in Germany	39
CD28-costimulated CD19 CAR-T cells for pediatric mature non-Hodgkin B-cell lymphoma	38
Autologous hematopoietic stem cell transplantation activity for lymphoma and multiple myeloma in China	38
Defining remission and relapse after allogeneic hematopoietic cell transplantation in myelodysplastic/myeloproliferative neoplasms and optimization of transplantation outcomes: Recommendations from th	35
Randomized phase 2 study of digital life coaching during transplantation for myeloma	33
The effect of posttransplant cyclophosphamide on ocular graft-versus-host disease	32
The impact of social determinants of health on outcomes of brexucabtagene autoleucel in adults with relapsed/refractory B-cell acute lymphoblastic leukemia	32
Combinatorial inhibition of Tec kinases BTK and ITK is beneficial in ameliorating murine sclerodermatous chronic graft versus host disease	32
Busulfan target exposure attainment in children undergoing allogeneic hematopoietic cell transplantation: a single day versus a multiday therapeutic drug monitoring regimen	31
Role of extracorporeal photopheresis in the management of acute and chronic graft versus disease: current status	31
Late hematologic toxicity after CAR T-cell therapy in large B-cell lymphoma: incidence, risk factors, and clinical impact	30
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with peripheral T-cell lymphoma	30
MRD-guided de-escalation of TBI conditioning in ALL	30

Prognostic significance of cytogenetic risk score in patients with secondary acute myeloid leukemia undergoing allogeneic stem cell transplantation from HLA-matched unrelated donors: a study from the	29
Artificial intelligence methods to estimate overall mortality and non-relapse mortality following allogeneic HCT in the modern era: an EBMT-TCWP study	28
Palliative care involvement for pediatric hematopoietic cell transplant patients can enhance comfort-focused care at end of life without shortening survival duration	27
CAR-T TEMRA and CAR-Tregs in vivo expansion are both associated with a poor response after CD19.CAR-T therapy	27
Cytokine release syndrome: implications for transplant outcomes in haploidentical and HLA-matched HSCT using PTCy	27
Which is older, Medicine or Wine?	26
Significant detrimental impact of pre-transplant mogamulizumab on the post-transplant outcome with a short interval between the last mogamulizumab and transplantation	26
Addition of ruxolitinib to standard graft-versus-host disease prophylaxis for allogeneic stem cell transplantation in aplastic anemia patients	26
Autologous stem cell boost improves persistent immune effector cell associated hematotoxicity following BCMA directed chimeric antigen receptor T (CAR T) cell therapy in multiple myeloma	26
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P762-P770)	26
Prior antibiotics exposure predicts early and prolonged CD19 CAR T-cell-related hematologic toxicity and prognosis in acute B-cell leukemia	24
The role of splenic irradiation prior to allogeneic hematopoietic stem transplantation in myelofibrosis: a review of the literature	24
Post-transplant cyclophosphamide, calcineurin inhibitor, and mycophenolate mofetil compared to anti-thymocyte globulin, calcineurin inhibitor, and methotrexate combinations as graft-versus-host diseas	24
Impact of prior solid tumors and their treatment modality on outcomes after allogeneic hematopoietic stem cell transplantation	24
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians - Oral Sessions (O009-O155)	24
The germline challenge in allogeneic transplantation: from donor selection to outcomes	23
Impact of center volume on outcomes in allogeneic hematopoietic cell transplantation for children	23
Trends in allogeneic hematopoietic cell transplantation survival using population-based descriptive epidemiology method: analysis of national transplant registry data	23
Haploidentical transplantation with post-transplant cyclophosphamide versus single cord blood transplantation in adults with relapsed/refractory non-Hodgkin lymphoma	23
Changing scenario in prevention and management of CMV infections in pediatric hematopoietic stem cell transplant patients	23
External validation and extended application of the transplant conditioning intensity score in acute myeloid leukemia	22
Bronchiectasis in patients with bronchiolitis obliterans syndrome: toward phenotyping BOS?	22
The effect of center experience on allogeneic hematopoietic cell transplantation outcomes in acute myeloid leukemia	22
Limited utility of chimeric antigen receptor (CAR) T-cell retreatment: experience with a human anti-CD19 CAR	21
Post-transplant cyclophosphamide compared to sirolimus/tacrolimus in reduced intensity conditioning transplants for patients with lymphoid malignancies	21
Busulfan plus cyclophosphamide vs. total body irradiation plus cyclophosphamide for allogeneic hematopoietic stem cell transplantation in patients with acute T lymphoblastic leukemia: a large-scale pr	21
High incidence of resistant breakthrough invasive fungal infections (IFD) in patients treated for acute gastrointestinal graft-versus-host disease (GI GVHD) following allogeneic haematopoietic cell tr	20
Eculizumab treatment in paediatric patients diagnosed with aHUS after haematopoietic stem cell transplantation: a HSCT-TMA case series from Japanese aHUS post-marketing surveillance	20
Acute myeloid leukemia after CAR T-cell therapy: role of pre-existing clonal hematopoiesis and inflammation in leukemogenesis	20
An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT	20
Allogeneic hematopoietic cell transplant in cutaneous T-cell lymphomas: recommendations from the EBMT PH&G Committee	20
Efficacy of eculizumab in transplantation-associated thrombotic microangiopathy: results of the French nationwide study on behalf of the SFGM-TC and the CNR-MAT	20
Individualized dose of anti-thymocyte globulin based on weight and pre-transplantation lymphocyte counts in pediatric patients: a single center experience	20
Outcome of haematopoietic cell transplantation in children with lysosomal acid lipase deficiency: a study on behalf of the EBMT Inborn Errors Working Party	20
SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination	19
Effect of graft-versus-host disease on outcomes of HLA-haploidentical peripheral blood transplantation using post-transplant cyclophophamide	19
Pre-transplant inflammation and its associations with acute GvHD and mortality in pediatric allogeneic hematopoietic stem cell transplantation patients	19
Hypophosphatemia and pre-infusion thrombocytopenia as biomarkers for CRS and ICANS after CAR T therapy	19
High-dose chemotherapy with autologous haematopoietic stem cell transplantation in patients with isolated vitreoretinal lymphoma: a LOC network study	19
Hematopoietic cell transplantation and cellular therapies in Europe 2022. CAR-T activity continues to grow; transplant activity has slowed: a report from the EBMT	19
Life 2.0: a comprehensive cross-sectional profiling of long-term allogeneic hematopoietic cell transplantation survivors compared to a matched general population cohort	18
Efficacy and safety of belumosudil for treatment of cGVHD: multicenter retrospective analysis of the French cohort of the compassionate use program, on behalf of the French Society of Bone Marrow Tran	18
The risk of anxiety and depression in Swedish potential stem cell donors—need for increased psychological evaluation and support?	18
Clostridium butyricum MIYAIRI 588 contributes to the maintenance of intestinal microbiota diversity early after haematopoietic cell transplantation	18
Tuberculosis after hematopoietic cell transplantation: retrospective study on behalf of the Infectious Diseases Working Party of the EBMT	18
An extraction pipeline for analysis of hematopoietic stem cell transplantation data	18
Autologous hematopoietic stem cell transplantation in severe, refractory stiff person syndrome: a case series	17
Incidence of cardiovascular disease in healthy Swedish peripheral blood stem cell donors – a nationwide study	17
Efficacy of eltrombopag for treatment of thrombocytopenia in the setting of allogeneic hematopoietic cell transplantation: a systematic review and meta-analysis	17
Shorter long-term post-transplant life expectancy may be due to prior chemotherapy for the underlying disease: analysis of 3012 patients with acute myeloid leukemia enrolled on 9 consecutive ECOG-ACRI	17

Return to school practices after hematopoietic cell transplantation: a survey of transplant centers in the United States	17
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O155-O159)	17
Donor lymphocyte infusion (DLI) post haploidentical stem cell transplantation (Haplo) with post-transplant cyclophosphamide (PTCy): crossing the human leukocyte antigen (HLA) barrier	17
Treosulfan-based double-alkylator conditioning in myelofibrosis: An Italian retrospective multicenter analysis	17
Allogeneic hematopoietic stem cell transplantation for adult acute myeloid leukemia patients with nucleoporin 98 (NUP98) gene rearrangements: a real-world study in China	16
GvHD prophylaxis with tacrolimus, sirolimus, and mycophenolate mofetil after reduced intensity conditioning hematopoietic stem cell allogeneic transplantation	16
Physical performance before and after hematopoietic stem cell transplantation in pediatric patients: a potential role for prehabilitation	16
Outcomes of patients undergoing allogeneic haematopoietic stem cell transplantation for congenital amegakaryocytic thrombocytopenia; a study on behalf of the PDWP of the EBMT	16
Non-myeloablative allogeneic stem cell transplant with fludarabine and reduced dose cyclophosphamide in acute myeloid leukemia for older adults with comorbidities	16
Molecular alterations monitoring in myelodysplastic patients receiving an allogeneic hematopoietic stem cell transplantation after a reduced-intensity conditioning regimen	16
Sociodemographic factors and timing of allogeneic hematopoietic stem cell transplantation in myeloproliferative neoplasms	16
Role and competencies of the EBMT clinical pharmacists and clinical pharmacologists: a pan-European survey	15
Ruxolitinib for the treatment of acute and chronic graft-versus-host disease in children: a systematic review and individual patient data meta-analysis	15
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P756-P761)	15
Racial and ethnic disparities in brain-to-vein time among patients receiving CD19 CAR-T cell therapy for relapsed/refractory DLBCL	15
Durable remission of refractory and advanced stage mycosis fungoides/sezary syndrome utilizing an “outpatient” alemtuzumab, fludarabine-based reduced intensity allogeneic hematopoietic cell transplant	15
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Poster Session (P709-P715)	15
Comparative study of treosulfan plus Fludarabine (FT14) with busulfan plus Fludarabine (FB4) for acute myeloid leukemia in first or second complete remission: An analysis from the European Society for	15
Decision making on HSCT in patients with hemoglobinopathies; an EBMT Pediatric Diseases Working Party and Inborn Errors Working Party scenario-based survey on physicians’ perspectives	15
Alemtuzumab treatment for steroid-refractory acute graft-versus-host disease leads to severe immunosuppression but not to relapse of malignant disease	14
Allogeneic hematopoietic cell transplantation for myelodysplastic syndrome unclassifiable – a retrospective study on behalf of the Chronic Malignancies Working Party of the EBMT	14
Relationship between morphologic remission with or without hematologic recovery and outcome after allogeneic hematopoietic cell transplantation in adult acute myeloid leukemia	14
Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP	14
Clofarabine and total body irradiation (TBI) as conditioning regimen for allogeneic stem cell transplantation in high-risk acute leukemia patients: a two-center retrospective cohort study	14
Autologous stem cell transplantation for AL amyloidosis: a multicenter summary of outcomes 2010–2020	14
Survival outcomes and risk factors of second allogeneic hematopoietic cell transplantation in non-remission status for acute myeloid leukemia	14
Efficacy and safety of relmacabtagene autoleucel, an anti-CD19 chimeric antigen receptor T cell, in relapsed/refractory B-cell non-Hodgkin’s lymphoma: 2-year results of a phase 1 trial	14
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Oral Session (O167-O168)	14
Progressive multifocal leukoencephalopathy after CAR-T cell therapy	13
Peripheral blood haploidentical hematopoietic cell transplantation for patients aged 70 years and over with acute myeloid leukemia or high-risk myelodysplastic syndrome	13
Impact of chronic graft-versus-host-disease on intensive care outcome in allogeneic hematopoietic stem cell recipients	13
A practical guide to therapeutic drug monitoring in busulfan: recommendations from the Pharmacist Committee of the European Society for Blood and Marrow Transplantation (EBMT)	13
Outcomes of allogeneic stem cell transplant in adult Philadelphia negative acute lymphoblastic leukemia patients treated with the pediatric-inspired GIMEMA 1913 protocol. A Campus ALL study	13
Myeloablative conditioning regimens in adult patients with acute myeloid leukemia undergoing allogeneic hematopoietic stem cell transplantation in complete remission: a systematic review and network m	13
Molecular measurable residual disease monitoring and transplant indications in NPM1 mutated acute myeloid leukemia	13
Role of consolidative radiotherapy in preventing relapses and subsequent salvage ASCT in early-stage classic Hodgkin lymphoma	13
Successful allogeneic hematopoietic stem cell transplantation in children with myeloid malignancies secondary to GATA2 deficiency using decitabine-containing busulfan conditioning	13
Allogeneic hematopoietic stem cell transplantation for adults with therapy-related acute myeloid leukaemia: a retrospective multicentre study on behalf of the SFGM-TC	13
Blood and marrow transplant within 4 weeks of SARS-CoV-2 infection is associated with increased risk of mortality: a National COVID Cohort Collaborative (N3C) Study	12
Outcome after Treosulfan-based conditioning in a real-world MDS cohort	12
Isocitrate dehydrogenase (IDH) 1 and 2 mutations predict better outcome in patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: a study of the ALWP of the EBM	12
Gifts, wine and blood	12
Post-thaw CD34+ cell recovery likely degraded under extreme graft platelet concentrations	12
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	12
Association of FLT3-ITD and NPM1 mutations with outcomes of allogeneic hematopoietic cell transplantation in acute myeloid leukemia	12
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Patient Advocacy – Oral Session (O164-O169)	12
Hematopoietic stem cell transplantation for pediatric patients with non-anaplastic peripheral T-cell lymphoma. An EBMT pediatric diseases working party study	12
Lung transplantation for pulmonary graft versus host disease: experience from a referral organ transplantation center	12
Early administration of selected CD34 peripheral blood stem cell following bone marrow transplantation to prevent graft rejection: experience in haploidentical transplant for sickle cell disease	12
Neglected tropical diseases (NTDs) and related infections in hematopoietic cellular therapy (HCT) in adults and children: a survey from the Infectious Diseases Working Party (IDWP) of the European Soc	12
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	12
CALR mutations possess unique prognostic relevance in myelofibrosis—before and after transplant	11
Prognostic impact of the conditioning intensity on outcomes after allogeneic transplantation for MDS with low blasts: a nationwide retrospective study by the adult MDS working group of the Japan Socie	11
“30 years of global collaboration in transplantation and cellular therapy: WMDA’s commitment to donor safety, ethical standards, and equitable access”	11
A phase 1 dose-escalation study of low-dose lenalidomide maintenance post-allogeneic stem cell transplantation for high-risk acute myeloid leukaemia or myelodysplastic syndrome	11
Feasibility of outpatient administration of ciltacabtagene autoleucel and reduction in healthcare utilization cost: the Vanderbilt experience	11
Toward functional cure in relapsed/refractory multiple myeloma: long-term outcomes from CARTITUDE-1 study cement the role of CAR-T cells	11
Cord blood is a suitable donor source of allogeneic hematopoietic cell transplantation for adult T-cell leukemia-lymphoma: a nationwide retrospective study	11
Rituximab added to conditioning regimen significantly improves erythroid engraftment in major incompatible ABO-group hematopoietic stem cell transplantation	11
Sexual function of adult long-term survivors and their partners after allogeneic hematopoietic cell transplantation in Europe (S-FAST): a study from the Transplant Complications Working Party and Nurs	11
Severity and organ distribution of chronic graft-versus-host disease with posttransplant cyclophosphamide-based versus methotrexate/calcineurin inhibitor-based allogeneic hematopoietic cell transplant	11
Posaconazole versus fluconazole as primary antifungal prophylaxis for patients at high risk of invasive fungal infections receiving allogeneic hematopoietic stem cell transplantation	11
The 50th Annual Meeting of the European Society for Blood and Marrow Transplantation: Physicians – Poster Session (P001-P755)	11
High-dose aciclovir in CMV infection prophylaxis after allogeneic HSCT: a single-center long-term experience	11
Comparing stem cell mobilization with chemotherapy and cytokine (G-CSF) versus cytokine alone in myeloma patients (MOCCCA): a randomized phase II, open-label, non-inferiority trial	11
A phase II multicenter prospective study to evaluate the safety and efficacy of myeloablative-dose treosulfan plus fludarabine (FT14) conditioning regimen in allogeneic hematopoietic stem cell transpl	11
Chronic graft-versus-host disease: Current situation and unmet needs — A European position statement	11
Comparison of fludarabine/melphalan (FluMel) with fludarabine/melphalan/BCNU or thiotepa (FBM/FTM) in patients with AML in first complete remission undergoing allogeneic hematopoietic stem cell transp	11
Late stenosis of the small intestine and colon, an atypical feature of chronic graft-versus-host disease. National retrospective study in French pediatric allograft centers	11
Bone marrow versus peripheral blood stem cells as the graft source for allogeneic transplantation from HLA-matched relative donors in adult T-cell leukemia/lymphoma: A nationwide retrospective study b	11
Timing of achieving MRD negativity for B-ALL patients with IKZF1 alterations in CR1 may dictate transplant decision: Autologous versus Allogeneic HSCT	11
Split dose ATG strategy prevents grade III-IV acute GVHD and is associated with immune surrogates of GVL	11
Cellular therapy in mantle cell lymphoma: recommendations from the EBMT practice harmonisation and guidelines committee	11
Allogeneic hematopoietic cell transplantation for patients with AML aged 70 years or older in first remission. A study from the Acute Leukemia Working Party of the European Society for Blood and Marro	11
Dual T cell depletion for graft versus host disease prevention in peripheral blood haploidentical hematopoietic cell transplantation for adults with hematological malignancies	11
Incidence and outcome of hemorrhagic cystitis after allogeneic hematopoietic cell transplantation: a survey of the infectious diseases working party of EBMT	11
No impact of CD34+ cell dose on outcome among children undergoing autologous hematopoietic stem cell transplant for high-risk neuroblastoma	10
Placental expanded mesenchymal-like cells (PLX-R18) for poor graft function after hematopoietic cell transplantation: A phase I study	10
Assessment of Cytomegalovirus DNA doubling time and virus-specific T-cell responses in the management of CMV infection in allogeneic hematopoietic stem cell transplant recipients undergoing Letermovir	10
Old age in patients and vines	10

Successful use of defibrotide to treat allogeneic hematopoietic stem cell transplantation associated thrombotic microangiopathy in pediatric patients: report from Chinese single center	10
Defining a lineage-specific chimerism threshold for the use of donor lymphocyte infusions in treating myeloid malignancies	10
Outcomes of toxoplasmosis after allogeneic hematopoietic stem cell transplantation and the role of antimicrobial prophylaxis	10
Microdissection testicular sperm extraction after pediatric allogeneic hematopoietic stem cell transplantation: a case series	10
The 48th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee – Poster Session (P590-P600)	10
HLA-B*15:01 and HLA-DRB1*07:01 as novel markers of acute GVHD in pediatric HSCT	10
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	10
Emapalumab for the Treatment of Immune-Mediated Graft Failure after HSCT	10
Impact of antithymocyte globulin usage and risk stratification for posttransplant lymphoproliferative disorders in aplastic anemia patients after allogeneic hematopoietic cell transplantation	10
Anti-T-lymphocyte globulin (ATLG) compared to post-transplant cyclophosphamide as GvHD prophylaxis in ALL patients undergoing allogeneic stem cell transplantation	10
Correction: Haploidentical hematopoietic stem cell transplantation for hematologic malignancies: a novel conditioning regimen with anti-T lymphocyte immunoglobulin instead of anti-thymocyte globulin f	10
aGvHDtrackR and cGvHDtrackR: shiny applications for graft versus host disease management and clinical data collection	10
CBFB::MYH11 MRD after the second chemotherapy cycle: a guide for allogeneic transplantation in favorable-risk AML	10
Tuberculosis after allogeneic hematopoietic stem cell transplantation: a decade nationwide case-control retrospective study in low-incidence country	10
Poor outcome of CHOEP induction followed by gemcitabine/busulfan/melphalan high-dose therapy and stem cell rescue for patients with newly diagnosed peripheral T-cell lymphoma	10
Allogeneic hematopoietic cell transplantation with sequential conditioning regimen in relapsed refractory acute myeloid leukemia	10
Favorable outcomes and the association between dynamic transfusion dependence and IPSS-M in MDS-h and MDS-LB patients undergoing allo-HSCT	10
Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates	9
Can modified lymphodepletion before tisagenlecleucel improve outcome in high-risk patients with large B-cell lymphoma?	9
GVHD prophylaxis with post-transplant cyclophosphamide results in lower incidence of GVHD and allows faster immunosuppressive treatment reduction compared to antithymocyte globulin in 10/10 HLA-matche	9
Impact of body mass index on outcomes following allogeneic hematopoietic stem cell transplantation	9
Allogeneic hematopoietic cell transplantation in patients with juvenile myelomonocytic leukemia in Korea: a report of the Korean Pediatric Hematology-Oncology Group	9
Psychosocial correlates of failure to complete hematopoietic stem cell transplants in a diverse population	9
Favorable outcomes following CD34-selected stem cell boost for poor graft function after allogeneic hematopoietic stem cell transplantation	9
Incidence of breakthrough COVID-19 in patients with hematological disorders who received pre-exposure prophylaxis with tixagevimab-cilgavimab: a retrospective study in Japan	9
Pure white cell aplasia following allogeneic hematopoietic stem cell transplantation	9
Smoking cessation among blood or marrow transplant Survivors: a BMTSS Report	9
A high hematopoietic cell transplantation comorbidity Index (HCT-CI) does not impair outcomes after non-myeloablative allogeneic stem cell transplantation in acute myeloid leukemia patients 60 years o	9
Are any specific respiratory viruses more severe than others in recipients of allogeneic stem cell transplantation? A focus on lower respiratory tract disease	9
Intermediate-dose TBI/fludarabine conditioning for allogeneic hematopoietic cell transplantation in patients with cutaneous T-cell lymphoma	9
Evaluation of risk for bronchiolitis obliterans syndrome after allogeneic hematopoietic cell transplantation with myeloablative conditioning regimens	9
Comparison of allo-SCT versus consolidation chemotherapy as post-remission therapy in acute lymphoblastic leukaemia aged ≥55 years	9
Upfront memory T cell add-back with haploidentical TCRαβ-depleted graft in adults with haematological malignancies: a nationwide, multicentre, single-arm, prospective study	9
Out of specification Tisagenlecleucel is associated with outcomes comparable to standard of care product in relapsed or refractory diffuse large B-cell lymphoma	9
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Organising committee	9
The effect of danger-associated molecular patterns on survival in acute graft versus host disease	9
Hematopoietic stem cell transplantation in pediatric congenital erythropoietic porphyria: a French retrospective multicenter registry study on behalf of the Francophone Society of Bone Marrow Transpla	9
Hematopoietic cell transplantation and cell therapy activity landscape survey in the Kingdom of Saudi Arabia; a report from the Saudi Society of Blood and Marrow Transplantation (SSBMT)	9
Predicting the loss of hepatitis B surface antigen following haematopoietic stem cell transplantation in patients with chronic HBV infection	9
Correction: The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation: Pharmacist Committee—Poster Session (P716-P724)	9
Better pre-transplant treatment options for TP53-mutated MDS: cytoreductive or non-cytoreductive therapy?	9
Age 60 or older is an independent predictor of outcomes after thiotepa-based autologous transplant in primary CNS lymphoma: a CIBMTR analysis	9
The 52nd Annual Meeting of the European Society for Blood and Marrow Transplantation: Psychiatry and Psychology Group – Oral Session (O172)	9
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Welcome Address	9
Efficacy of artesunate for treatment of cytomegalovirus reactivation post allogeneic haematopoietic stem cell transplants	9
“The antibiotic paradox” in allogeneic stem cell transplantation	9
Graft engineering: how long can you wait, how low can you go, and pandemic readiness	9
Influence of comorbidities on outcome in 1102 patients with an allogeneic hematopoietic stem cell transplantation	8
Impact of donor age on cognitive recovery in allogenic hematopoietic stem cell transplant patients with mild cognitive impairment	8
Hematopoietic cell transplantation and cellular therapies in Europe 2021. The second year of the SARS-CoV-2 pandemic. A Report from the EBMT Activity Survey	8
Association between human herpesvirus-6 encephalitis and antiviral prophylaxis after allogeneic hematopoietic stem cell transplantation in the letermovir era	8
Efficacy of CD19 directed therapies in patients with relapsed or refractory large b-cell lymphoma relapsing after CD19 directed chimeric antigen receptor T-cell therapy	8
Von Willebrand factor as a potential predictive biomarker of early complications of endothelial origin after allogeneic hematopoietic stem cell transplantation	8
Efficacy of SARS-CoV-2 primary and booster vaccine doses in CAR-T recipients – targeting the target antigen	8
Exposure to antibiotics with anaerobic activity before respiratory viral infection is associated with respiratory disease progression after hematopoietic cell transplant	8
Allogeneic haematopoietic cell transplantation for therapy-related myeloid neoplasms arising following treatment for lymphoma: a retrospective study on behalf of the Chronic Malignancies Working Party	8
Is myelo-ablative pretransplant conditioning really myelo-ablative: Implications for radiation and nuclear accidents?	8
Haploidentical allogeneic stem cell transplantation with post-transplant cyclophosphamide and subsequent kidney transplant for patients with severe sickle cell disease with end-stage kidney disease (E	8
Impact of graft CD34+ cell counts on hematological recovery in patients receiving post-transplant cyclophosphamide prophylaxis	8
EASIX and sC5b-9 for early identification of adults at high risk of developing TA-TMA after allo-HCT	8
CMV prophylaxis with letermovir significantly improves graft and relapse free survival following allogeneic stem cell transplantation	8
Modified umbilical cord-blood transplantation for pediatric patients with mucopolysaccharidosis	8
Letermovir prophylaxis lowers the incidence of Non-CMV infections after allogeneic hematopoietic cell transplantation	8
Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation	8
Herpes simplex virus reactivation among hematopoietic stem cell transplant recipients: re-evaluating acyclovir dosage	8
Long term results of a prospective multicenter observational study on the use of anti-human T-lymphocyte immunoglobulin (ATLG) in unrelated donor transplantation (ATOS study)	8
Von Willebrand factor and factor VIII as potential biomarkers for diagnosis and disease monitoring in chronic graft-versus-host disease	8
Venetoclax is safe and tolerable as post-transplant maintenance therapy for AML patients at high risk for relapse	8
In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chron	8
The 49th Annual Meeting of the European Society for Blood and Marrow Transplantation:  Quality Management Group – Oral Session (O176)	8
Real-world outcomes of tandem ASCT in newly diagnosed multiple myeloma patients with standard risk features: a single-center analysis	8
Risk factors and long-term outcomes for human herpesvirus 6 encephalitis in the early period after allogeneic stem cell transplantation	8
Prophylactic versus Preemptive modified donor lymphocyte infusion for high-risk acute leukemia after allogeneic hematopoietic stem cell transplantation: a multicenter retrospective study	8
Development and validation of an automated computational approach to grade immune effector cell-associated hematotoxicity	8
Ofatumumab as part of reduced intensity conditioning in high risk B-cell lymphoma patients: final long-term analysis from a prospective multicenter Phase-II Trial	8
Prognostic factors in 448 newly diagnosed multiple myeloma receiving bortezomib-based induction: impact of ASCT, transplant refusal and high-risk MM	8
The impact of individual comorbidities in transplant recipients receiving post-transplant cyclophosphamide	8
Gastrointestinal involvement refines prognosis in minnesota standard risk acute graft-vs.-host disease	8
Machine learning-based prediction of G-CSF-induced hematopoietic stem cell mobilization outcomes in healthy volunteers	8
The 51st Annual Meeting of the European Society for Blood and Marrow Transplantation: Lectures	8
A clinical solution for tracking clonal evolution of acute myeloid leukemia after allogeneic transplantation using bulk next generation sequencing	8
Monitoring for virus-specific T-cell responses and viremia in allogeneic HSCT recipients: a survey from the EBMT Cellular Therapy & Immunobiology Working Party	7
Nutrition support and clinical outcomes following allogeneic stem cell transplantation	7
Current therapeutics for sclerotic and fibrotic manifestations of chronic graft-versus-host disease	7
Relapse patterns focusing on central nervous system involvement after allogeneic hematopoietic cell transplantation in adult patients with acute lymphoblastic leukemia	7
Haploidentical vs. mismatched unrelated donor transplants with posttransplant cyclophosphamide-based GVHD prophylaxis	7
Protection of haematopoietic progenitor cell donors: an updated overview of the European landscape	7
Outcomes of primary graft failure in acute myeloid leukemia patients following unrelated transplantation with post-transplant cyclophosphamide: a study from the ALWP/EBMT	7
Reconsidering the role of bone marrow as a graft source in haploidentical allogeneic hematopoietic cell transplantation	7
Use of eculizumab in children with allogeneic haematopoietic stem cell transplantation associated thrombotic microangiopathy - a multicentre retrospective PDWP and IEWP EBMT study	7
Correction: Impact of custom prime on the PBSC collection efficiency and procedure outcome on Spectra Optia apheresis device by using the CMNC program in low-weight pediatric oncology patients. A sing	7
Is sex chromosome loss a predictive marker for outcome after sex-mismatched allogeneic hematopoietic stem cell transplantation?	7
Comparison of outcomes of BuCy versus BuCyMel as preparation for allogeneic HSCT in infants with acute myeloid leukemia in first complete remission: a multicenter study from the EBMT PDWP	7
The use of mesenchymal stromal cells in steroid-refractory graft-versus-host disease after pediatric hematopoietic stem cell transplantation: a report of the Spanish group of stem cell transplantation	7
Salvage haploidentical transplantation for graft failure after first haploidentical allogeneic stem cell transplantation: an updated experience	7